Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

MLA

Hendrickson, Ronald C., et al. “Identification of a 17beta-Hydroxysteroid Dehydrogenase Type 12 Pseudogene as the Source of a Highly Restricted BALB/c Meth A Tumor Rejection Peptide.” Cancer Immunology, Immunotherapy : CII, vol. 59, no. 1, Jan. 2010, pp. 113–24. EBSCOhost, https://doi.org/10.1007/s00262-009-0730-7.

APA

Hendrickson, R. C., Cicinnati, V. R., Albers, A., Dworacki, G., Gambotto, A., Pagliano, O., Tüting, T., Mayordomo, J. I., Visus, C., Appella, E., Shabanowitz, J., Hunt, D. F., & DeLeo, A. B. (2010). Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide. Cancer Immunology, Immunotherapy : CII, 59(1), 113–124. https://doi.org/10.1007/s00262-009-0730-7

Chicago

Hendrickson, Ronald C, Vito R Cicinnati, Andreas Albers, Grzegorz Dworacki, Andrea Gambotto, Ornella Pagliano, Thomas Tüting, et al. 2010. “Identification of a 17beta-Hydroxysteroid Dehydrogenase Type 12 Pseudogene as the Source of a Highly Restricted BALB/c Meth A Tumor Rejection Peptide.” Cancer Immunology, Immunotherapy : CII 59 (1): 113–24. doi:10.1007/s00262-009-0730-7.